Home › Research › Drug development
Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update
Huang LK, Kuan YC, Lin HW, Hu CJ.. Journal of biomedical science, 2023-10-02
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and neuronal injury. Clinical trials focusing on new drugs for AD were documented in 2020, but subsequent developments have emerged since then.
What this study adds
Evidence grade: Low
This is a narrative review. This update reviews Alzheimer drug trials from 2020 to 2023 and notes that the FDA approved aducanumab and lecanemab, both amyloid-targeting antibodies, ending nearly two decades without new Alzheimer drugs. It is a report on the trial landscape, not evidence that these drugs cure or prevent the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Huang, L. K., Kuan, Y. C., Lin, H. W., & Hu, C. J. (2023). Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update. Journal of biomedical science. https://doi.org/10.1186/s12929-023-00976-6
Vancouver
Huang LK, Kuan YC, Lin HW, Hu CJ. Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update. Journal of biomedical science. 2023. doi:10.1186/s12929-023-00976-6. PMID: 37784171.
BibTeX
@article{huang2023-37784171,
author = {Huang, L. K. and Kuan, Y. C. and Lin, H. W. and Hu, C. J.},
title = {{Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update}},
journal = {Journal of biomedical science},
year = {2023},
doi = {10.1186/s12929-023-00976-6},
pmid = {37784171},
url = {https://doi.org/10.1186/s12929-023-00976-6}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and neuronal injury.
- Clinical trials focusing on new drugs for AD were documented in 2020, but subsequent developments have emerged since then.
- Notably, the US-FDA has approved Aducanumab and Lecanemab, both antibodies targeting amyloid, marking the end of a nearly two-decade period without new AD drugs.
- In this comprehensive report, we review all trials listed in clinicaltrials.gov, elucidating their underlying mechanisms and study designs.
Why it matters
This update reviews Alzheimer drug trials from 2020 to 2023 and notes that the FDA approved aducanumab and lecanemab, both amyloid-targeting antibodies, ending nearly two decades without new Alzheimer drugs. It is a report on the trial landscape, not evidence that these drugs cure or prevent the disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of biomedical science) |
| Journal's citation record | 2 / 4 | Journal of Biomedical Science: journal h-index 151 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 250 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 50.0 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 5 / 6 | Cited 36.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 4 / 4 | Cited 245 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Chaur‐Jong Hu: h-index 48 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | National Taiwan University: institution h-index 752 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37784171) |
| Free to read | 2 / 2 | Free to read |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s12929-023-00976-6
- PubMed: 37784171
- Original source →
- Free full text: Journal of Biomedical Science →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 23.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Drug development from nearby years
Also in Drug development
107 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.